

1 Supplementary Materials for “Female mice lacking estrogen receptor  $\beta$  display  
2 excitatory/inhibitory synaptic imbalance to drive the pathogenesis of temporal lobe  
3 epilepsy”.

4

5 Figure S1. Correlation analyses of ER $\beta$  expression and clinical features in female  
6 TLE patients.

7 Figure S2. ER $\beta$  expression was down-regulated in OVX chronic epileptic mice.

8 Figure S3. ER $\beta$  deletion increased seizure susceptibility in OVX acute epileptic mice.

9 Figure S4. ER $\beta$  deletion exacerbated pathological changes of OVX chronic epileptic  
10 mice.

11 Figure S5. ER $\beta$  deletion did not affect dendritic branches and classification in CA1  
12 pyramidal neurons of OVX chronic epileptic mice.

13 Figure S6. Hierarchical clustering and GO enrichment analysis for DEGs co-regulated  
14 by ER $\beta$  and epilepsy.

15 Table S1. Clinical features of female patients with TLE.

16 Table S2. Clinical features of control subjects.

17 Table S3. The sequences of qRT-PCR primers used in this study.


18

19

20

21


22



24 **Figure S1. Correlation analyses of ER $\beta$  expression and clinical features in female**  
 25 **TLE patients. (A, B)** Spearman rank correlation between ER $\beta$  expression and seizure  
 26 frequency in temporal neocortex (A) and hippocampus (B) of female TLE patients.  
 27 There were negative correlations between ER $\beta$  expression and seizure frequency in  
 28 temporal neocortex ( $n = 8$ ,  $r = -0.7776$ ,  $P = 0.0231$ ) and hippocampus ( $n = 5$ ,  $r =$   
 29  $-0.9307$ ,  $P = 0.0217$ ) of female TLE patients. **(C, D)** Spearman rank correlation  
 30 between ER $\beta$  expression and Wechsler intelligence scores in temporal neocortex (C)  
 31 and hippocampus (D) of female TLE patients. There were positive correlations  
 32 between ER $\beta$  expression and Wechsler intelligence score in temporal neocortex ( $n = 8$ ,

33  $r = 0.7257$ ,  $P = 0.0416$ ) and hippocampus ( $n = 5$ ,  $r = 0.8882$ ,  $P = 0.0441$ ) of female  
34 TLE patients.

35 **Figure S2**



36 **Figure S2. ERβ expression was down-regulated in OVX chronic epileptic mice.**

37 (A) Immunostaining of ERβ in the cortex and hippocampus of OVX chronic epileptic

38 mice and OVX control mice ( $n = 5$  in each group). Scale bars, 50  $\mu\text{m}$ . (B)

39 Quantification of ERβ in immunostaining. MOD of ERβ was decreased in the cortex,


40 CA1 and CA3 regions of OVX chronic epileptic mice compared with controls. The

41 data were shown as means  $\pm$  SEM. Significance was calculated using ANOVA,

42 followed by Tukey's test.  $*P < 0.05$ .

43 **Figure S3**


44



45 **Figure S3. ER $\beta$  deletion increased seizure susceptibility in OVX acute epileptic**  
 46 **mice. (A) Diagram of experimental paradigm. (B, C) Representative basal and acute**  
 47 **epileptic EEG recordings from the cortex (B) and hippocampus (C) of OVX mice. (D,**  
 48 **E) Spectral analysis of acute epileptic EEG recordings. ER $\beta$  deletion increased  $\theta$ ,  $\alpha$ ,  $\beta$**   
 49 **oscillations in cortex (D) and  $\theta$ ,  $\alpha$ ,  $\beta$ ,  $\gamma_1$  oscillations in hippocampus (E) of OVX**

50 acute epileptic mice. (F-I) Seizure behavioral score (F), average latency (G), number  
 51 (H) and time (I) of seizures before SE in OVX acute epileptic mice. ERβ deletion  
 52 increased seizure behavioral scores, number, and time of seizures before SE, and  
 53 decreased the latency of acute seizures. N = 5 in each group. The data were shown as  
 54 means ± SEM. Significance was calculated using Student's *t* test. \**P* < 0.05, \*\**P* <  
 55 0.01.


56 **Figure S4**



57 **Figure S4. ERβ deletion exacerbated pathological changes of OVX chronic**  
 58 **epileptic mice. (A)** Immunostaining of GFAP in the CA1 and CA3 regions of each  
 59 group of OVX mice. ERβ deletion aggravated the gliosis in the CA1 and CA3 regions

60 of OVX chronic epileptic mice. **(B)** Nissl staining in the CA1 and CA3 regions of  
 61 each group of OVX mice. ER $\beta$  deletion aggravated the neuron loss of the CA1 and  
 62 CA3 regions in OVX chronic epileptic mice. **(C)** Timm staining in the CA1 and CA3  
 63 regions of each group of OVX mice. ER $\beta$  deletion aggravated moss fibers sprouting  
 64 in the CA3 region of OVX chronic epileptic mice, but did not affect moss fibers  
 65 sprouting in the CA1 region. Scale bars, 50  $\mu$ m. N = 5 in each group. The data were  
 66 shown as means  $\pm$  SEM. Significance was calculated using ANOVA, followed by  
 67 Tukey's test. \* $P < 0.05$ , \*\* $P < 0.01$ .


68 **Figure S5**



69 **Figure S5. ER $\beta$  deletion did not affect dendritic branches and classification in**  
 70 **CA1 pyramidal neurons of OVX chronic epileptic mice. (A, B) Representative**  
 71 **image (A) and reconstruction (B) of CA1 pyramidal neurons from OVX mice (n = 3**

72 in each group). (C, G) Dendritic branches of CA1 pyramidal neurons. Both of apical  
 73 (C) and basal (G) dendritic branches were decreased in CA1 pyramidal neurons of  
 74 OVX chronic epileptic mice, but ER $\beta$  deletion did not affect the dendritic branches of  
 75 CA1 pyramidal neurons. (D-F) Classification of dendritic spines in CA1 apical  
 76 pyramidal neurons. (H-J) Classification of dendritic spines in CA1 basal pyramidal  
 77 neurons. The proportion of mushroom dendritic spines was decreased and the  
 78 proportion of thin dendritic spines were increased in CA1 pyramidal neurons of OVX  
 79 chronic epileptic mice compared with OVX controls. ER $\beta$  deletion did not change the  
 80 classification of dendritic spines in CA1 pyramidal neurons from OVX mice. There  
 81 were no changes in the proportion of stubby dendritic spines in CA1 pyramidal  
 82 neurons from OVX mice. The data were shown as means  $\pm$  SEM. Significance was  
 83 calculated using ANOVA, followed by Tukey's test. \* $P < 0.05$ , \*\* $P < 0.01$ .

84 **Figure S6**



85 **Figure S6. Hierarchical clustering and GO enrichment analysis for DEGs**  
 86 **co-regulated by ER $\beta$  and epilepsy.** (A) Hierarchical clustering analysis of  
 87 co-regulated DEGs. (B) GO enrichment analysis of co-regulated DEGs.

88

89 **Table S1. Clinical features of female patients with TLE.**

Case No.	Gender	Diagnosis	Age at surgery (year)	Epilepsy duration (year)	Seizure frequency (month)	Seizure type	Location of surgical resection	Engel's class	Application in this study
1	F	TLE	48	6.5	45	PS;	L temporal	II	IHC,
2	F	TLE	34	2	72	PS; IS;	R temporal	II	IHC,
3	F	TLE	58	2.5	57	PS;	R temporal, R hippocampus	I	WB, IHC,
4	F	TLE	23	5	21	PS;	L temporal	I	IHC,
5	F	TLE	31	4	42	GTCS;	R temporal	I	IHC,
6	F	TLE	33	4	106	PS; GTCS;	L temporal, L hippocampus	II	WB, IHC,
7	F	TLE	23	3	45	PS;	L temporal	I	IHC,
8	F	TLE	64	1	57	PS;	L temporal, L hippocampus	I	IHC,
9	F	TLE	54	8	92	GTCS;	R temporal	I	WB,
10	F	TLE	51	7	34	PS; Tonic;	L temporal	II	WB, IHC,
11	F	TLE	40	5.5	22	GTCS;	L temporal	I	IHC,
12	F	TLE	29	3.5	43	PS;	R temporal, R hippocampus	I	WB,
13	F	TLE	27	2	27	PS;	R temporal	II	IHC,
14	F	TLE	65	5.5	57	PS;	L temporal	III	IHC,
15	F	TLE	46	3	35	GTCS; Tonic;	R temporal, R hippocampus	II	WB, IHC,
16	F	TLE	33	4	21	GTCS;	L temporal	I	WB,
17	F	TLE	59	2	31	GTCS;	L temporal, L hippocampus	I	WB, IHC,

F, Female; TLE, temporal lobe epilepsy; PS, partial seizure; IS, infantile spasm; GTCS, generalized tonic-clonic seizure; Tonic, tonic seizure; WB, Western blot; IHC, immunohistochemistry

90 **Table S2. Clinical features of control subjects.**

Case No.	Gender	Age (year)	Cause of death	PMI (h)	Location of resection	Seizure	Application in the present study
1	F	16	Motor vehicle accident	2.0	L temporal; L hippocampus	None	WB, IHC
2	F	41	Non-neurological disease	3.0	R temporal	None	IHC
3	F	27	Non-neurological disease	4.5	L temporal	None	WB
4	F	36	Motor vehicle accident	2.2	L temporal; L hippocampus	None	WB, IHC
5	F	45	Non-neurological disease	3.6	R temporal	None	WB, IHC,
6	F	57	Non-neurological disease	2.1	L temporal	None	WB,
7	F	22	Motor vehicle accident	1.7	R temporal; R hippocampus	None	WB, IHC



8	F	38	Non-neurological disease	3.0	R temporal	None	IHC
9	F	47	Non-neurological disease	2.8	L temporal	None	WB, IHC
10	F	32	Motor vehicle accident	2.4	L temporal	None	IHC
11	F	56	Non-neurological disease	4.0	R temporal	None	IHC
12	F	16	Non-neurological disease	3.5	L temporal	None	WB, IHC

91 **Table S3. The sequences of qRT-PCR primers used in this study.**

Gene name	Forward	Reverse
Grm4	CCCATACCCATTGTCAAGTTGG	TGTAGCGCACAAAAGTGACCA
Slcla3	ACCAAAAAGCAACGGAGAAGAG	GGCATTCCGAAACAGGTAAGTC
Grm8	ATGGTTTGTGAGGGAAAGCG	GAATGGGCATACTCCTGGCT
GLUL	TGAACAAAGGCATCAAGCAAATG	CAGTCCAGGGTACGGGTCTT
Cacna1c	ATGAAAACACGAGGATGTACGTT	ACTGACGGTAGAGATGGTTGC
Nsf	CGGACTATGCAAGCTGCGA	AACCGCACAGTTGCTTAAAGA
GAPDH	AGGTCGGTGTGAACGGATTTG	GGGGTCGTTGATGGCAACA

92